115P - Male breast cancer - A single institution review

Date 18 December 2016
Event ESMO Asia 2016 Congress
Session Poster lunch
Topics Breast Cancer, Locally Advanced
Presenter Nisha Hariharan
Citation Annals of Oncology (2016) 27 (suppl_9): ix30-ix34. 10.1093/annonc/mdw576
Authors N. Hariharan, T..S. Rao, C. C K Naidu, S. Patnaik, R.R. Iyer
  • Surgical Oncology, Basavatarakam Indo American Cancer Hospital and Research Institute, 500034 - Hyderabad/IN



Male breast cancer is a clinical rarity. In contrast to the detailed clinical data and randomised trials available on female breast cancer, only case series and retrospective audits are available for male breast cancer. We attempted to review our institution data from the past 5 years to add to the information available on this subject


We reviewed the prospectively collected data between 2010 and 2015 for this study. All male patients with histologically proven breast cancer and available clinical data for analysis were included. Patients with gynaecomastia were excluded. We evaluated the clinical presentation, treatment given, histopathological differences and outcomes for this group of patients.


Of the 5020 breast cancer patients who underwent treatment in our institute between 2010 and 2015, we identififed 36 male patients. Of these, 21 patients met the inclusion criteria. Two thirds of them had central quadrant tumors while the remaining presented with tumors in the upper outer quadrant. 66% presented as locally advanced cancers (LABC) while the remaining were operable at presentation. None of the patients were denovo metastatic. Among the LABC, skin or muscle involvement occurred early, with half of them (n = 7) being clinically T4. Matted nodes accounted for the remaining half of the LABC. Almost all of them were planned for upfront radical mastectomy except one who received anterior chemotherapy followed by surgery. The tumor histology was universally invasive ductal in nature. 28.5% of patients were node negative on final histopathology. The 3 year DFS for the whole group was 80.9%. Among the node positives, it was 73.3%.


Male breast cancer forms less than 1% of all the breast cancers. They are universally invasive ductal in histology and tend to occur most frequently in the central quadrant with early skin and/or muscle involvement. 71.5% are node positive on final pathology. The 3 year DFS among node positive patients is 73.3%. This worse prognosis compared to female breast cancer could be due to the early involvement of skin/muscle or lymph nodes. Larger data series is necessary to throw more light on this rare entity.

Clinical trial indentification

Legal entity responsible for the study

Basavatarakam Indo American Cancer Hospital and Research Institute


Basavatarakam Indo American Cancer Hospital and Research Institute


All authors have declared no conflicts of interest.